Robin Stevenson
Directeur/Membre du Conseil chez Avelas Biosciences, Inc.
Profil
Robin Stevenson is currently a Non-Executive Director at Avelas Biosciences, Inc. He started this position in 2021 and is still currently employed there.
Prior to this, he was a Director at The Breast Cancer Research Trust.
Postes actifs de Robin Stevenson
| Sociétés | Poste | Début |
|---|---|---|
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Directeur/Membre du Conseil | 18/10/2021 |
Anciens postes connus de Robin Stevenson
| Sociétés | Poste | Fin |
|---|---|---|
The Breast Cancer Research Trust
 The Breast Cancer Research Trust Medical SpecialtiesHealth Technology The Breast Cancer Research Trust operates as not-for profit organization. It provides breast cancer treatment solutions. The company was founded in 1997 and is headquartered in Auckland, New Zealand. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
The Breast Cancer Research Trust
The Breast Cancer Research Trust Medical SpecialtiesHealth Technology The Breast Cancer Research Trust operates as not-for profit organization. It provides breast cancer treatment solutions. The company was founded in 1997 and is headquartered in Auckland, New Zealand. | Health Technology |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |